Clinical trials: Uremic Pruritis
Uremic Pruritus
A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session.
- Trial name
- NCT03422653
- Testing
- CR845 0.5 mcg/kg
- Where
- 57 sites in United States
- Volunteers
- 378 people
- Sponsor
- Cara Therapeutics, Inc.
Uremic Pruritus
A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
Double-blind, Placebo-controlled study to evaluate the dose-response relationship of safety, efficacy and pharmacokinetics of MA13A9 in hemodialysis patients with pruritus.
- Trial name
- NCT03802617
- Testing
- MR13A9
- Where
- Japan
- Volunteers
- 247 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Pruritis
Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients
The purpose of this research study is to evaluate the efficacy of SARNA Sensitive Lotion in the treatment of uremic pruritus in adult hemodialysis patients in a double-blind Controlled comparative trial.
- Trial name
- NCT00693654
- Testing
- Sarna, Cetaphil
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Wake Forest University
Uremic Pruritus
Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients
A Randomized, Double Blind, Placebo-Controlled study to assess the Safety, Local Tolerance, and Pharmacokinetics of LT5001 drug product in Hemodialysis Patients with Uremic Pruritus
- Trial name
- NCT04393675
- Testing
- LT5001
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Uremic Pruritus, Pruritus
Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
The primary objectives of the study to evaluate the effects of two doses of nalbuphine HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in hemodialysis patients with moderate to severe…
- Trial name
- NCT02143648
- Testing
- nalbuphine HCl ER tablets 60 mg BID, nalbuphine HCl ER tablets 120mg BID
- Where
- 47 sites in United States, Poland and 1 more
- Volunteers
- 373 people
- Sponsor
- Trevi Therapeutics
Chronic Kidney Diseases, Pruritus
A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of 3 dose levels of oral CR845 compared to placebo in reducing the intensity of itch in chronic kidney disease (CKD)…
- Trial name
- NCT03617536
- Testing
- CR845 0.25 mg Oral Tablet, CR845 0.5 mg Oral Tablet, CR845 1 mg Oral Tablet
- Where
- 60 sites in United States
- Volunteers
- 269 people
- Sponsor
- Cara Therapeutics, Inc.
Uremic Pruritus
Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
2 Part Study: Part A will assess 3 different dosing levels of IV CR845 versus placebo in patient on hemodialysis who have moderate-to-severe itching due to uremic pruritus.
- Trial name
- NCT02858726
- Testing
- CR845 0.5 mcg/kg, CR845 1 mcg/kg, CR845 1.5mcg/kg
- Where
- 29 sites in United States
- Volunteers
- 226 people
- Sponsor
- Cara Therapeutics, Inc.
Uremic Pruritus
CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
This is a multicenter, open-label study to evaluate the safety and effectiveness of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes an up to 12-week Treatment Period.
- Trial name
- NCT03998163
- Testing
- CR845 0.5 mcg/kg
- Where
- 47 sites in United States, Czechia and 2 more
- Volunteers
- 222 people
- Sponsor
- Cara Therapeutics, Inc.
Uremic Pruritus
The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease
The purpose of this study was to confirm the efficacy of NB UVB phototherapy in alleviating uremic pruritus and investigate the association between improvement of pruritus and change of serum parameters, including routine…
- Trial name
- NCT00494975
- Testing
- Narrow band UVB phototherapy , long wave UVA phototherapy
- Where
- Taiwan
- Volunteers
- 21 people
- Sponsor
- National Taiwan University Hospital
Pruritus, Cholestasis
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
This first in human, Phase 1/1b trial will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of EP547 in healthy subjects and subjects with cholestatic or uremic pruritus.
- Conditions
- Pruritus, Cholestasis, Kidney Failure
- Trial name
- NCT04510090
- Testing
- EP547
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Escient Pharmaceuticals, Inc
Uremia
Evaluation of the Efficacy of Laser Acupuncture on Uremic Pruritus
Sixty patients were randomly assigned to either the experimental group (n=30) receiving laser acupuncture or the control group (n=30) receiving sham laser acupuncture. Treatment sessions were conducted during dialysis sessions.
- Trial name
- NCT06875115
- Testing
- laser acupuncture
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Dalin Tzu Chi General Hospital
Uremic Pruritus
Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.
- Trial name
- NCT03281538
- Testing
- CR845
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 288 people
- Sponsor
- Cara Therapeutics, Inc.
Uremic Pruritus
A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
Double-blind, Placebo-controlled study to confirm the superiority of MR13A9 to placebo, and followed by extension, open-label treatment to confirm long-term safety of MA13A9 in hemodialysis patients with pruritus.
- Trial name
- NCT04711603
- Testing
- MR13A9
- Where
- Japan
- Volunteers
- 178 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Uremic Pruritus, Pruritus
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 24 weeks.
- Trial name
- NCT02143973
- Testing
- nalbuphine HCl ER
- Where
- 35 sites in United States
- Volunteers
- 167 people
- Sponsor
- Trevi Therapeutics
Uremic Pruritus
Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis
This study is being conducted to investigate the efficacy of MT-9938 compared with placebo after 2 weeks, to continue to evaluate efficacy for an additional 6 weeks, and to explore the effect of a reduction in itching intensity…
- Trial name
- NCT01660243
- Testing
- Nalfurafine hydrochloride(MT-9938) 2.5μg, Nalfurafine hydrochloride(MT-9938) 5μg, Nalfurafine hydrochloride(MT-9938) 10μg
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Toray Industries, Inc
Uremic Pruritus
Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
This a multicentre study that consists of a 12-week double-blind period, and an optional 14-week open-label extension period and a 1-week follow-up period.
- Trial name
- NCT05885737
- Testing
- Difelikefalin Injection
- Where
- 35 sites in China
- Volunteers
- 260 people
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
Uremic Pruritus
CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
This is a multicenter, international study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session.
- Trial name
- KALM-2 (NCT03636269)
- Testing
- CR845 0.5 mcg/kg
- Where
- 92 sites in United States, Australia and 9 more
- Volunteers
- 473 people
- Sponsor
- Cara Therapeutics, Inc.